SLV 310

Drug Profile

SLV 310

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Solvay
  • Class Antipsychotics; Phthalimides; Pyridines
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Psychotic disorders

Most Recent Events

  • 06 Apr 2004 Solvay and Wyeth Pharmaceuticals formed a worldwide agreement to co-develop and co-commercialise SLV 310
  • 28 Jan 2003 Phase-II clinical trials in Psychotic disorders (unspecified route)
  • 31 Jul 2000 Phase-I clinical trials for Psychotic disorders (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top